SubHero Banner
Text

February 2018

Core topics in this month’s edition include:

  • Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) – new drug approval
  • Symdeko (tezacaftor/ivacaftor and ivacaftor) – new drug approval
  • Namenda XR (memantine) – first time generic

Download PDF

Text